Safety and Efficacy of Nivolumab in Patients With Advanced Non–small-cell Lung Cancer Treated Beyond Progression

Introduction Treatment with immune checkpoint inhibitors beyond progression is associated with improved survival in patients with melanoma and clear-cell renal carcinoma. Whether this association exists for patients with non–small-cell lung cancer (NSCLC) is currently still unclear. Patients and Methods We performed a multi-institutional retrospective study based on landmark and multivariable analyses to evaluate the safety and efficacy of...